HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 5 (2008), Issue 6 (June)

1. Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity.
   J Leukoc Biol, 83(6): 1530-40. [Abstract] [Full-text]
2. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.
   Clin Infect Dis, 47(1): 102-4. [Abstract] [Full-text]
3. Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments.
   J Am Chem Soc, 130(23): 7184-5. [Abstract] [Full-text]
4. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro.
   Nucleic Acids Res, 36(10): 3389-400. [Abstract] [Full-text]
5. Effect of transcription peptide inhibitors on HIV-1 replication.
   Virology, 376(2): 308-22. [Abstract] [Full-text]
6. Natural history and risk factors associated with early and established HIV type 1 infection among reproductive-age women in Malawi.
   Clin Infect Dis, 46(12): 1913-20. [Abstract] [Full-text]
7. Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors.
   Blood, 111(12): 5537-43. [Abstract] [Full-text]
8. Protective role of DC-SIGN (CD209) neck-region alleles with <5 repeat units in HIV-1 transmission.
   J Infect Dis, 198(1): 68-71. [Abstract] [Full-text]
9. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
   J Infect Dis, 198(1): 59-67. [Abstract] [Full-text]
10. Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: the advantage of heterozygosity for coding mutations.
    J Infect Dis, 198(1): 72-80. [Abstract] [Full-text]
11. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    J Infect Dis, 198(1): 51-8. [Abstract] [Full-text]
12. Efficient and stable gene expression into human osteoclasts using an HIV-1-based lentiviral vector.
    DNA Cell Biol, 27(6): 315-20. [Abstract] [Full-text]
13. Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorg Med Chem, 16(12): 6353-63. [Abstract] [Full-text]
14. Sexual activity and Kaposi's sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men.
    Ann Epidemiol, 18(7): 517-21. [Abstract] [Full-text]
15. HIV-1 Nef protein expression in human CD34+ progenitors impairs the differentiation of an early T/NK cell precursor.
    Virology, 377(1): 207-15. [Abstract] [Full-text]
16. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
    Virology, 377(1): 49-53. [Abstract] [Full-text]
17. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
    Virology, 377(1): 170-83. [Abstract] [Full-text]
18. Recombinant protein of heptad-repeat HR212, a stable fusion inhibitor with potent anti-HIV action in vitro.
    Virology, 377(1): 80-7. [Abstract] [Full-text]
19. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
    Virology, 377(1): 71-9. [Abstract] [Full-text]
20. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    J Theor Biol, 253(1): 24-35. [Abstract] [Full-text]
21. A novel CD4-conjugated ultraviolet light-activated photocatalyst inactivates HIV-1 and SIV efficiently.
    J Med Virol, 80(8): 1322-31. [Abstract] [Full-text]
22. Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.
    J Med Virol, 80(8): 1319-21. [Abstract] [Full-text]
23. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
    J Mol Biol, 380(3): 504-19. [Abstract] [Full-text]
24. In vitro expression of the HIV-2 genomic RNA is controlled by three distinct internal ribosome entry segments that are regulated by the HIV protease and the Gag polyprotein.
    RNA, 14(7): 1443-55. [Abstract] [Full-text]
25. Genotypic resistance testing in HIV by arrayed primer extension.
    Anal Bioanal Chem, 391(5): 1661-9. [Abstract] [Full-text]
26. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.
    Lancet, 371(9630): 2109-19. [Abstract] [Full-text]
27. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide.
    Biochemistry, 47(26): 6782-92. [Abstract] [Full-text]
28. Conformational transitions of flanking purines in HIV-1 RNA dimerization initiation site kissing complexes studied by CHARMM explicit solvent molecular dynamics.
    Biopolymers, 89(9): 732-46. [Abstract] [Full-text]
29. Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.
    Clin Exp Immunol, 153(1): 37-43. [Abstract] [Full-text]
30. Structural mobility of the monomeric C-terminal domain of the HIV-1 capsid protein.
    FEBS J, 275(13): 3299-311. [Abstract] [Full-text]
31. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters.
    J Acquir Immune Defic Syndr, 48(3): 241-4. [Abstract] [Full-text]
32. Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.
    J Acquir Immune Defic Syndr, 48(3): 255-62. [Abstract] [Full-text]
33. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.
    J Acquir Immune Defic Syndr, 48(3): 281-8. [Abstract] [Full-text]
34. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
    J Acquir Immune Defic Syndr, 48(3): 324-33. [Abstract] [Full-text]
35. p24 as a predictor of mortality in a cohort of HIV-1-infected adults in rural Africa.
    J Acquir Immune Defic Syndr, 48(3): 345-9. [Abstract] [Full-text]
36. HIV-1 DNA in peripheral blood mononuclear cells is strongly associated with HIV-1 disease progression in recently infected West African adults.
    J Acquir Immune Defic Syndr, 48(3): 350-4. [Abstract] [Full-text]
37. Host genetic influences on highly active antiretroviral therapy efficacy and AIDS-free survival.
    J Acquir Immune Defic Syndr, 48(3): 263-71. [Abstract] [Full-text]
38. Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women.
    J Acquir Immune Defic Syndr, 48(3): 245-54. [Abstract] [Full-text]
39. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study.
    J Acquir Immune Defic Syndr, 48(3): 315-23. [Abstract] [Full-text]
40. Monitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution.
    J Virol, 82(14): 7022-33. [Abstract] [Full-text]
41. CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing.
    J Virol, 82(14): 7155-66. [Abstract] [Full-text]
42. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
    J Virol, 82(14): 6869-79. [Abstract] [Full-text]
43. Infection with Vpr-positive human immunodeficiency virus type 1 impairs NK cell function indirectly through cytokine dysregulation of infected target cells.
    J Virol, 82(14): 7189-200. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.